Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Defence Therapeutics (OTCQB: DTCFF) will attend CPHI Worldwide 2025 in Frankfurt, Germany from October 28-30, 2025, the company stated on October 6, 2025. According to the press release, Defence plans to engage potential partners across the biopharma value chain, learn about pharmaceutical manufacturing trends, and connect with international collaborators and shareholders.
The company also invited attendees to an informal Meet & Greet on October 29, 2025 from 4:30–6:30 PM at the American May lobby bar of the Kimpton Hotel in Frankfurt and listed contact options via the CPHI partnering platform and LinkedIn for named company representatives.
Defence Therapeutics (OTCQB: DTCFF) parteciperà a CPHI Worldwide 2025 a Francoforte, Germania, dal 28 al 30 ottobre 2025, ha dichiarato l’azienda il 6 ottobre 2025. Secondo il comunicato stampa, Defence intende coinvolgere potenziali partner lungo la catena del valore biopharma, conoscere le tendenze della produzione farmaceutica e connettersi con collaboratori internazionali e azionisti.
L’azienda invita inoltre i partecipanti a un informal Meet & Greet il 29 ottobre 2025 dalle 16:30 alle 18:30 presso il bar della lobby American May dell’hotel Kimpton a Francoforte e ha indicato opzioni di contatto tramite la piattaforma di partenariato CPHI e LinkedIn per i rappresentanti nominati dell’azienda.
Defence Therapeutics (OTCQB: DTCFF) asistirá a CPHI Worldwide 2025 en Fráncfort, Alemania, del 28 al 30 de octubre de 2025, según informó la empresa el 6 de octubre de 2025. Según el comunicado, Defence planea involucrar a posibles socios a lo largo de la cadena de valor biofarmacéutica, conocer las tendencias de fabricación farmacéutica y conectarse con colaboradores y accionistas internacionales.
La empresa también invitó a los asistentes a un informal Meet & Greet el 29 de octubre de 2025 de 4:30 a 6:30 PM en el bar American May de la lobby de la Kimpton Hotel en Fráncfort y listó opciones de contacto a través de la plataforma de asociación de CPHI y LinkedIn para representantes designados de la empresa.
Defence Therapeutics (OTCQB: DTCFF)가 프랑크푸르트, 독일에서 열리는 CPHI Worldwide 2025에 2025년 10월 28일부터 30일까지 참석한다고 2025년 10월 6일 발표했다. 보도자료에 따르면 Defence는 바이오의약품 가치 사슬 전반의 잠재적 파트너를 모색하고, 제약 제조 동향을 파악하며, 국제 협력자 및 주주들과의 네트워크를 구축할 계획이다.
또한 2025년 10월 29일 오후 4:30~6:30에 프랑크푸르트의 Kimpton Hotel American May 로비 바에서 비공식 Meet & Greet를 개최하는 초청과 함께 회사 대표를 위한 CPHI 파트너링 플랫폼과 LinkedIn을 통한 연락 방법도 안내했다.
Defence Therapeutics (OTCQB: DTCFF) assistera à CPHI Worldwide 2025 à Francfort, Allemagne, du 28 au 30 octobre 2025, selon l’entreprise le 6 octobre 2025. Selon le communiqué, Defence prévoit de s’engager avec des partenaires potentiels sur toute la chaînne de valeur biopharmaceutique, d’en apprendre davantage sur les tendances de fabrication pharmaceutique et de se connecter avec des coopérateurs et des actionnaires internationaux.
L’entreprise a également invité les participants à une rencontre informelle Meet & Greet le 29 octobre 2025 de 16h30 à 18h30 au bar du hall American May de l’hôtel Kimpton à Francfort et a indiqué des options de contact via la plate-forme de partenariats CPHI et LinkedIn pour des représentants nommés de l’entreprise.
Defence Therapeutics (OTCQB: DTCFF) wird an der CPHI Worldwide 2025 in Frankfurt, Deutschland, vom 28. bis 30. Oktober 2025 teilnehmen, teilte das Unternehmen am 6. Oktober 2025 mit. Der Pressemitteilung zufolge plant Defence, potenzielle Partner entlang der Biopharma-Wertschöpfungskette zu gewinnen, sich über Trends in der pharmazeutischen Herstellung zu informieren und mit internationalen Kooperationspartnern und Aktionären in Kontakt zu treten.
Das Unternehmen lud außerdem die Teilnehmer zu einem informellen Meet & Greet am 29. Oktober 2025 von 16:30 bis 18:30 Uhr in die American May Lobby Bar des Kimpton Hotels in Frankfurt ein und nannte Kontaktmöglichkeiten über die CPHI-Partnering-Plattform und LinkedIn für benannte Unternehmensvertreter.
Defence Therapeutics (OTCQB: DTCFF) ستشارك في CPHI Worldwide 2025 في فرانكفورت، ألمانيا، من 28 إلى 30 أكتوبر 2025، وفقاً لما أعلنت الشركة في 6 أكتوبر 2025. ووفقاً للبيان الصحفي، تخطط Defence لجذب شركاء محتملين عبر سلسلة قيمة المستحضرات الحيوية الدوائية، والتعرّف على اتجاهات تصنيع الأدوية، والتواصل مع شركاء ومساهمين دوليين.
كما دعت الشركة الحضور أيضاً إلى اجتماع غير رسمي Meet & Greet في 29 أكتوبر 2025 من 4:30 إلى 6:30 مساءً في بار الردهة الأمريكية في فندق Kimpton بفرانكفورت وأشارت إلى خيارات الاتصال عبر منصة شراكة CPHI ولينكدإن للممثلين المعينين للشركة.
Defence Therapeutics (OTCQB: DTCFF) 将出席在德国法兰克福举行的 CPHI Worldwide 2025,时间为 2025 年 10 月 28 日至 30 日,该公司在 2025 年 10 月 6 日宣布。根据新闻稿,Defence 计划在生物制药价值链上接触潜在合作伙伴,了解制药制造趋势,并与国际协作者及股东建立联系。
公司还邀请与会者参加 2025 年 10 月 29 日下午 4:30–6:30 的非正式 Meet & Greet,地点在法兰克福 Kimpton 酒店 American May 大堂酒吧,并通过 CPHI 合作平台和 LinkedIn 为指定的公司代表提供联系方式。
- None.
- None.
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 2025.
At this premier gathering and global trade fair of pharmaceutical leaders, Defence looks forward to engaging with potential partners across the biopharma value chain and with the global pharma community, learning about the latest trends in pharmaceutical manufacturing, and connecting with its international collaborators and shareholders.
In addition to its conference participation, Defence warmly invites attendees, partners, and shareholders in the region to join its leadership team for an informal Meet & Greet on Wednesday, October 29 from 4:30-6:30 PM at the American May lobby bar of the Kimpton Hotel in Frankfurt. This networking event will provide an opportunity to meet the team, exchange insights, and explore partnership opportunities in a relaxed setting.
Interested in meeting our team? Reach out through the CPHI conference partnering platform or connect with our leaders who will be at the meeting via LinkedIn: Amie Phinney, Strategy and Business Advisory, Mark Lambermon, Head of Quality and Operations (our in-house German speaker!) or Sebastien Plouffe, CEO. And of course, don't hesitate to just drop-by the Meet & Greet event.
About CPHI:
CPHI (www.cphi.com) is a leading global pharmaceutical trade show and networking platform, bringing together tens of thousands of industry professionals from more than 160 countries. In the 2025 edition in Frankfurt, over 62,000 visitors and around 2,400 exhibiting companies are expected, with more than 180 international speakers featured.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/269108